Medpace Q2 Revenue Beats by $20M, Backlog Conversion Drives 17% Growth
MEDP sits 62% above its 52-week low of $373.
Summary
Medpace delivered a strong Q2, with revenue of $707.33M beating consensus by nearly $20M on 17% year-over-year growth. Net income rose to $121.36M, and the backlog conversion rate hit 24.1%, signaling efficient execution. New business awards surged 28% to $796M, supporting the raised full-year guidance of $2.805B-$2.885B in revenue and EPS of $17.25-$17.95. The company also repurchased $295M in shares during the quarter, underscoring confidence. This follows a May governance overhaul and a June executive appointment, adding to a narrative of operational momentum. The stock, trading near its 52-week high, may see further upside as the beat and guidance exceed the subdued analyst consensus (average rating: hold).
At the time of this announcement, MEDP was trading at $605.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.1B. The 52-week trading range was $373.00 to $628.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.